GW Pharmaceuticals

www.gwpharm.com

Sovereign House Vision Park
Histon
Cambridge
Cambs
CB24 9BZ
United Kingdom

+44 (0) 1223 266800

Activities

Ingredients | Research & Development

Related Companies

Related Content

GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
GW Pharmaceuticals gains product recognition by NHS England
GW Pharmaceuticals gains product recognition by NHS England
Momentum in the US cannabidiol market gains retailers' attention
Momentum in the US cannabidiol market gains retailers' attention
First prescription CBD from GW Pharma has restriction lowered
First prescription CBD from GW Pharma has restriction lowered
First plant-derived cannabinoid prescription gains FDA approval
First plant-derived cannabinoid prescription gains FDA approval
GW Pharmaceuticals receives orphan drug designation for cannabidiol
GW Pharmaceuticals receives orphan drug designation for cannabidiol
GW Pharmaceuticals announces appointments to Board of Directors
GW Pharmaceuticals announces appointments to Board of Directors
GW Pharmaceuticals R&D Management appointments
GW Pharmaceuticals R&D Management appointments
GW Pharmaceuticals appoints new CFO and MD
GW Pharmaceuticals appoints new CFO and MD
GW receives FDA fast track and EMA orphan designations for intravenous cannabidiol
GW receives FDA fast track and EMA orphan designations for intravenous cannabidiol
High hopes for cannabis
High hopes for cannabis
GW appoints President, North America and relocates CEO to the US
GW appoints President, North America and relocates CEO to the US
Kenneth Sommerville joins GW Pharmaceuticals as VP of Clinical Science
Kenneth Sommerville joins GW Pharmaceuticals as VP of Clinical Science
Sativex moved to Schedule 4 of UK Drugs Act
Sativex moved to Schedule 4 of UK Drugs Act
Christopher Tovey joins GW Pharmaceuticals
Christopher Tovey joins GW Pharmaceuticals